Related Experiment Video

Updated: Jun 27, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies

Rita Khoury1, Chris Raffoul2, Colette Hanna1

  • 1Division of Hematology & Oncology, Lebanese American University Medical Center-Rizk Hospital, Beirut P.O. Box 11-3288, Lebanon.

International Journal of Molecular Sciences
|June 26, 2026
PubMed

Insights

EGFR mutations drive non-small cell lung cancer (NSCLC). While targeted therapies like osimertinib improve outcomes, resistance develops. New strategies are emerging to overcome resistance and improve patient survival in EGFR-mutant NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
  • Activating EGFR mutations are key drivers in a significant proportion of NSCLC patients, particularly in Asian populations.
  • EGFR tyrosine kinase inhibitors (TKIs) have revolutionized NSCLC treatment, with osimertinib showing significant progression-free and overall survival benefits.

Purpose of the Study:

  • To review current strategies for overcoming resistance to EGFR TKIs in NSCLC.
  • To highlight emerging therapeutic approaches for EGFR-mutant NSCLC.
  • To discuss the mechanisms of resistance to EGFR TKIs and their clinical implications.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of resistance mechanisms to first-, second-, and third-generation EGFR TKIs.
  • Exploration of novel therapeutic strategies including next-generation TKIs, combination therapies, and immunotherapy.

Main Results:

  • Resistance to EGFR TKIs is a major clinical challenge, often mediated by secondary mutations (e.g., T790M, C797S) or pathway amplifications (e.g., MET, HER2).
  • Diverse resistance mechanisms necessitate a multi-faceted approach to treatment.
  • Emerging therapies show promise in targeting resistance pathways and improving outcomes.

Conclusions:

  • Understanding EGFR TKI resistance mechanisms is crucial for developing effective treatment strategies.
  • Next-generation TKIs, combination therapies, and novel agents offer potential to overcome resistance.
  • Personalized therapeutic approaches are essential for optimizing patient care in EGFR-mutant NSCLC.
Keywords:
EGFR inhibitors resistanceEGFR mutationNSCLC

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...